Rubedo Life Sciences Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Rubedo Life Sciences is a clinical-stage biopharmaceutical company based in Sunnyvale, California, focused on developing therapies for aging-related chronic diseases. Its ALEMBIC platform merges single-cell multi-omics data, AI-enabled analysis, and disease biology to identify disease-relevant cell states and advance first-in-class therapies with precision activity across aging-associated indications. The company is advancing Adaptive Senotherapeutics, a state-dependent approach that aims to selectively remove pathogenic senescent cells while preserving or restoring function in damaged but recoverable cells.

Its lead program, RLS-1496, is described as a first-in-class GPX4 modulator targeting pathologic senescent cells in age-related dermatologic conditions, with early clinical signals such as target engagement and biomarker modulation. In May 2025, Rubedo announced the first patient had been dosed in the program's Phase 1 trial. Rubedo's work seeks to translate the biology of cellular senescence into medicines intended for dermatologic, fibrotic, pulmonary, oncologic, neurodegenerative, and other chronic disorders.

Get verified Rubedo Life Sciences emails free

Company overview Employee directory